



LAS VEGAS PSYCH SERVICES

2341 A Renaissance Drive
Las Vegas, NV 89119
Tel: (702) 405-9080
Fax: (702) 405-9240
Email: reception@txlv.com

Date: June 8, 2021

Silver State Scripts Board
State of Nevada, Department of Health and Human Services
Division of Health Care Financing and Policy (DHCFP)
1210 South Valley View Blvd Suite 104
Las Vegas, Nevada 89102

Re: SSSB Meeting for June 24, 2021 Psychotropic Agents-Antipsychotics-Atypical Antipsychotics-Oral
is item 6d on the agenda

I understand that there will be a review of Antipsychotics-Oral on the PDL at the June 24, 2021 Silver State Scripts Board. I would like to request that Caplyta (lumateperone) be available on the PDL as Preferred status for patients with Schizophrenia.

This letter is to provide written testimony of my clinical support of such approval. Since the launch of Caplyta, I have over a dozen patients on Caplyta. I have found that Caplyta is efficacious and tolerable for my Schizophrenic patients.

Caplyta is an important addition in the treatment armamentarium for adult patients with schizophrenia. The achievement of efficacy while maintaining a favorable safety and tolerability profile in weight change, metabolic side effects and motor disturbances represents a significant advance as these adverse events are commonly.

Thank you

Paul Nguyen, M.D.